We read with interest the paper by McGill and Levitsky [1] . As the authors point out, progress in the field of treatment of diabetes in children and adolescents as well as in adults with type 1 diabetes is needed. Insulin administration has substantially improved over the last 20 years, with the availability of insulin analogues and of insulin pumps. An unmet need is still represented by prevention and treatment of hypoglycemia, and euglycemia without acute metabolic complications still remains a major goal of management in type 1 diabetes. Not only hypoglycemia is an emergency itself but fear of hypoglycemia can limit optimal glycemic control in many children and adolescents as well as in adults with type 1 diabetes.
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Treatment of hypoglycemia can be based on administration of glucose or of glucagon; the latter is more popular in North America than in Europe, but the available preparations for intramuscular or subcutaneous injection still require reconstitution in syringes of glucagon powder and diluent that have to be stored separately because of instability of glucagon in solution. This is difficult for patients and caregivers and can lead to serious mistakes in administration [2] .
The notion of intranasal glucagon as a remedy for hypoglycemia is an old story; in 1983, it was shown that intranasal glucagon raises blood glucose in humans [3] , and in 1989, it was shown that intranasal glucagon was effective as intramuscular glucagon in treating hypoglycemia [4] . It was also shown that intranasal glucagon powders are as effective as intranasal glucagon solutions [5] , and this was probably an important step to eliminate the need for solutions. However, at that time, the pharmaceutical industry did not take the opportunity to develop intranasal glucagon; this happened around 2010, thanks to a Canadian company (Locemia Solutions, Montreal, Canada). The data reported by the authors under ref. 41 [6] are the result of the efforts of that company together with the T1D registry in adults, while evidence of a positive effect of intranasal glucagon on children and adolescents had been published earlier [2] . Due to its simple use, if intranasal glucagon could be brought to the market and to regular use, it might represent a universal remedy for hypoglycemia in children, adolescents, and adults with type 1 diabetes and in all insulin-treated patients with diabetes. 
